Last reviewed · How we verify
Mobilization with G-CSF and Mozobil
Mobilization with G-CSF and Mozobil is a Small molecule drug developed by Proteonomix, Inc.. It is currently in Phase 1 development. Also known as: Filgrastim, Neupogen, Plerixafor, AMD3100.
At a glance
| Generic name | Mobilization with G-CSF and Mozobil |
|---|---|
| Also known as | Filgrastim, Neupogen, Plerixafor, AMD3100 |
| Sponsor | Proteonomix, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Base Editing for Mutation Repair in Hematopoietic Stem & Progenitor Cells for X-Linked Chronic Granulomatous Disease (PHASE1, PHASE2)
- Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma (PHASE2)
- Base-Edited Hematopoietic Stem/Progenitor Cell X-Linked Severe Combined Immunodeficiency Gene Therapy (PHASE1, PHASE2)
- Pilot Study of Memory-like Natural Killer (ML NK) Cells After TCRαβ T Cell Depleted Haploidentical Transplant in AML (PHASE1, PHASE2)
- Protocol Title: Safety and Feasibility of Autologous CD34+ Hematopoietic Stem Cells Mobilization and Apheresis in Participants With RUNX1 Familial Platelet Disorder (PHASE1)
- Stem Cell Transplant With or Without Tbo-filgrastim in Treating Patients With Multiple Myeloma or Non-Hodgkin Lymphoma (PHASE2)
- Mozobil for Autologous Hematopoietic Stem Cell Transplantation (PHASE2)
- Genetically Modified T-cell Infusion Following Peripheral Blood Stem Cell Transplant in Treating Patients With Recurrent or High-Risk Non-Hodgkin Lymphoma (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Mobilization with G-CSF and Mozobil CI brief — competitive landscape report
- Mobilization with G-CSF and Mozobil updates RSS · CI watch RSS
- Proteonomix, Inc. portfolio CI
Frequently asked questions about Mobilization with G-CSF and Mozobil
What is Mobilization with G-CSF and Mozobil?
Mobilization with G-CSF and Mozobil is a Small molecule drug developed by Proteonomix, Inc..
Who makes Mobilization with G-CSF and Mozobil?
Mobilization with G-CSF and Mozobil is developed by Proteonomix, Inc. (see full Proteonomix, Inc. pipeline at /company/proteonomix-inc).
Is Mobilization with G-CSF and Mozobil also known as anything else?
Mobilization with G-CSF and Mozobil is also known as Filgrastim, Neupogen, Plerixafor, AMD3100.
What development phase is Mobilization with G-CSF and Mozobil in?
Mobilization with G-CSF and Mozobil is in Phase 1.
Related
- Manufacturer: Proteonomix, Inc. — full pipeline
- Also known as: Filgrastim, Neupogen, Plerixafor, AMD3100